May 9, 2016-The Institute for Clinical and Economic Review (ICER) has released a Draft Evidence Report, titled Diabetes Prevention Programs: Effectiveness and Value, for public comment. This is a draft version of the Evidence Report that will serve as the basis for deliberation and discussion at an upcoming meeting of the California Technology Assessment Forum (CTAF) on June 24, 2016
The report evaluates the clinical effectiveness and value of diabetes prevention programs with full or pending recognition from the Centers for Disease Control and Prevention Diabetes Prevention Recognition Program. The report also provides a snapshot of the policy and practice landscape based on information gathered from interviews with key stakeholders, including program vendors, payers, purchasers, and patient-focused organizations.
The Draft Evidence Report, as well as the accompanying draft voting questions, will be open to public comment until May 23, 2016 at 5:00 PM PT. All stakeholders are encouraged to submit formal comments to ensure that ICER’s report adequately considers each perspective. Comments should be emailed to firstname.lastname@example.org, and guidelines for submitting public comments, including formatting specifications, are available on the ICER website. ICER will review all comments received and incorporate relevant changes in an Evidence Report that will be posted on or about June 6, 2016.
The updated Evidence Report will be the subject of the June 24th CTAF public meeting, during which the independent CTAF panel will vote on key questions raised in the report, and a policy roundtable will discuss recommendations to apply the evidence to policy and practice. During the meeting, there will be a limited amount of time available for interested stakeholders to make oral comments on the report. Requests to make oral comments should be submitted to email@example.com by 5:00 PM PT on Friday, June 17, 2016.
The Institute for Clinical and Economic Review (ICER) is an independent non-profit research institute that produces reports analyzing the evidence on the effectiveness and value of drugs and other medical services. ICER’s reports include evidence-based calculations of prices for new drugs that accurately reflect the degree of improvement expected in long-term patient outcomes, while also highlighting price levels that might contribute to unaffordable short-term cost growth for the overall health care system.
ICER’s reports incorporate extensive input from all stakeholders and are the subject of public hearings through three core programs: the California Technology Assessment Forum (CTAF), the Midwest Comparative Effectiveness Public Advisory Council (Midwest CEPAC) and the New England Comparative Effectiveness Public Advisory Council (New England CEPAC). These independent panels review ICER’s reports at public meetings to deliberate on the evidence and develop recommendations for how patients, clinicians, insurers, and policymakers can improve the quality and value of health care. For more information about ICER, please visit ICER’s website.